<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01058070</url>
  </required_header>
  <id_info>
    <org_study_id>1306-US, 1030-IT, 1709-NL</org_study_id>
    <nct_id>NCT01058070</nct_id>
    <nct_alias>NCT01057992</nct_alias>
    <nct_alias>NCT01058564</nct_alias>
  </id_info>
  <brief_title>An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter</brief_title>
  <official_title>An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torax Medical Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torax Medical Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function&#xD;
      in the treatment of Gastroesophageal Reflux Disease (GERD)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this feasibility study is to collect preliminary performance and safety&#xD;
      information and develop procedural optimization for the Torax Medical Inc. Magnetic&#xD;
      Esophageal Sphincter device (MES) in reinforcement of Esophageal Sphincter function to treat&#xD;
      Gastroesophageal Reflux Disease (GERD). The information from this study will be used to&#xD;
      support the design and conduct of an expanded clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate the Incidence of All Adverse Events at Various Time Points.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Monitor the Improvement of GERD Symptoms.</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Implantable Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Torax Medical, Inc. LINX Reflux Management System</intervention_name>
    <description>Implantable device, Magnetic Esophageal Sphincter</description>
    <arm_group_label>Implantable Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years, &lt; 85 years, life expectancy &gt; 3yrs.&#xD;
&#xD;
          -  Documented history of GERD symptoms such as heartburn and/or regurgitation.&#xD;
&#xD;
          -  On daily PPI treatment for at least 3-months.&#xD;
&#xD;
          -  Responsive to PPI treatment.&#xD;
&#xD;
          -  GERD symptoms, in absence of PPI therapy (minimum 10 days).&#xD;
&#xD;
          -  Ambulatory Esophageal pH &lt; 4 for ≥ 5% time or pH &lt; 4 for ≥ 3% time in supine position.&#xD;
&#xD;
          -  Patient is a surgical candidate.&#xD;
&#xD;
          -  Patient is willing and able to cooperate with follow-up examinations.&#xD;
&#xD;
          -  Patient has been informed of the study procedures and the treatment and has signed an&#xD;
             informed consent form and provided authorization to use and disclose information for&#xD;
             research purposes (HIPAA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The procedure is an emergency procedure.&#xD;
&#xD;
          -  Patient is currently being treated with another investigational drug or&#xD;
             investigational device.&#xD;
&#xD;
          -  Patient has had prior gastric or esophageal surgery.&#xD;
&#xD;
          -  Patient has had any previous endoscopic intervention for GERD&#xD;
&#xD;
          -  Patient has suspected or confirmed esophageal or gastric cancer.&#xD;
&#xD;
          -  Patient has any size paraesophageal hiatal hernia or sliding hiatal hernia ≥3cm.&#xD;
             (Investigator to identify and record type of hiatal hernia at the time of assessment&#xD;
             (i.e. para-esophageal, sliding)).&#xD;
&#xD;
          -  Patient's esophageal motility is less than 35 mmHg peristaltic amplitude on wet&#xD;
             swallows or &gt; 30% failed (non-propulsive) peristaltic sequences.&#xD;
&#xD;
          -  Patient has esophagitis - Grade B, C, D (LA Classification).&#xD;
&#xD;
          -  Patient has Barretts Esophagus.&#xD;
&#xD;
          -  Patient has BMI &gt; 35.&#xD;
&#xD;
          -  Patient has symptoms of dysphagia or indications of dysphagia from barium esophagram.&#xD;
&#xD;
          -  Patient has Scleroderma and/or Achalasia.&#xD;
&#xD;
          -  Patient has an esophageal stricture or gross esophageal anatomic abnormalities&#xD;
             (obstructive lesions, etc.).&#xD;
&#xD;
          -  Patient has an electrical implant or metallic, abdominal implant(s).&#xD;
&#xD;
          -  Patient cannot understand trial requirements or is unable to comply with follow-up&#xD;
             schedule.&#xD;
&#xD;
          -  Patient is pregnant or nursing, or plans to become pregnant.&#xD;
&#xD;
          -  Patient has a psychiatric disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ganz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Gastroenterolgy, PA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California, Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapman Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92869</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bonavina L, Saino GI, Bona D, Lipham J, Ganz RA, Dunn D, DeMeester T. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg. 2008 Dec;12(12):2133-40. doi: 10.1007/s11605-008-0698-1. Epub 2008 Oct 10.</citation>
    <PMID>18846406</PMID>
  </reference>
  <reference>
    <citation>Bonavina L, DeMeester T, Fockens P, Dunn D, Saino G, Bona D, Lipham J, Bemelman W, Ganz RA. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg. 2010 Nov;252(5):857-62. doi: 10.1097/SLA.0b013e3181fd879b.</citation>
    <PMID>21037442</PMID>
  </reference>
  <reference>
    <citation>Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Fockens P, Bemelman W. The LINX® reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc. 2012 Oct;26(10):2944-9. Epub 2012 Apr 27.</citation>
    <PMID>22538694</PMID>
  </reference>
  <reference>
    <citation>Saino G, Bonavina L, Lipham JC, Dunn D, Ganz RA. Magnetic Sphincter Augmentation for Gastroesophageal Reflux at 5 Years: Final Results of a Pilot Study Show Long-Term Acid Reduction and Symptom Improvement. J Laparoendosc Adv Surg Tech A. 2015 Oct;25(10):787-92. doi: 10.1089/lap.2015.0394. Epub 2015 Oct 5.</citation>
    <PMID>26437027</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2010</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>May 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.8" lower_limit="19.0" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" lower_limit="19.0" upper_limit="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% time esophageal pH&lt;4</title>
          <description>The time during which esophageal pH is less than 4.0 divided by the total recording time expressed in percentage.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.9" lower_limit="2.7" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL)</title>
          <description>Scoring scale is from 0 to 5 with 0=no symptoms to 5=symptoms are incapacitating. The maximum value score is 50.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" lower_limit="10.0" upper_limit="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate the Incidence of All Adverse Events at Various Time Points.</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LINX Study Subjects</title>
            <description>Subjects implanted with LINX device</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate the Incidence of All Adverse Events at Various Time Points.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Monitor the Improvement of GERD Symptoms.</title>
        <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Implantable Device</title>
            <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
          </group>
        </group_list>
        <measure>
          <title>To Monitor the Improvement of GERD Symptoms.</title>
          <description>Percentage of participants with a 50% or more reduction in total GERD-HRQL score is indicative of a substantial improvement in GERD symptoms</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Pre-discharge, 2-Weeks, 6-Weeks, 3-Months, 6-Months, 12-Months, 18-Months, 24-Months, 30-Months, 36-Months, 42-Months, 48-Months, 54-Months, and 60-Months Follow-up</time_frame>
      <desc>An adverse event (AE) is any undesirable/unusual experience that occurs to a subject during the clinical study, whether or not considered device related, including, (but not limited to) those events that result from the use as stipulated in the protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Implantable Device</title>
          <description>Torax Medical, Inc. LINX Reflux Management System: Implantable device, Magnetic Esophageal Sphincter</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting &amp; Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting &amp; Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Stomach bloating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Inability to belch or vomit</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>No improvement</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Device explant/reoperation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Affairs</name_or_title>
      <organization>Torax Medical, Inc.</organization>
      <phone>651-361-8900</phone>
      <email>aderosier@toraxmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

